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Abstract
Objective
Understanding human immunity to Mycobacterium tuberculosis (Mtb) during different
stages of infection is important for development of an effective tuberculosis (TB) vaccine.
We aimed to evaluate immunity to Mtb infection by measuring immune responses to
selected Mtb antigens expressed during different stages of infection over time and to
observe sustainability of immunity.
Methods
In a cohort study comprising East Greenlanders aged 17–22 years (2012 to 2014) who had
either; undetectable Mtb infection, ongoing or prior Mtb infection at enrolment, we measured
immunity to 15 antigens over a one-year period. Quantiferon-TB Gold testing (QFT) defined
Mtb infection status (undetected/detected). The eligible study population of East Greenlan-
ders aged 17–22 years was identified from the entire population using the Civil Registration
System. From the source population 65 participants were selected by stratified random
sampling according to information on Mtb infection stage. Retrospective and prospective
information on notified TB (including treatment) was obtained through the mandatory TB
notification system and was used to characterise Mtb infection stage (ongoing/prior). Immu-
nity to 15 antigens including two QFT antigens, PPD and 12 non-QFT antigens (represent-
ing early, constitutive and latent Mtb infection) was assessed by measuring immune
responses using whole-blood antigen stimulation and interferon gamma measurement.
Results
Of 65 participants, 54 were considered Mtb-infected. Immunity to Mtb infection fluctuated
with high annual risk of conversion (range: 6–69%) and reversion (range: 5–95%). During
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follow-up, five (8%) participants were notified with TB; neither conversion nor reversion was
associated with an increased risk of progressing to TB.
Conclusions
Our findings suggest that human immunity to natural Mtb infection over time is versatile with
fluctuations, resulting in high levels of conversion and reversion of immunity, thus human
immunity to Mtb is much more dynamic than anticipated. The study findings suggest future
use of longitudinal assessment of immune responses when searching for TB vaccine candi-
date antigens.
Introduction
Tuberculosis (TB) will remain a major global health challenge, with an estimated two billion
individuals infected, unless new preventive measures are identified [1,2].
Mtb infection is traditionally classified as either latent Mtb infection (LTBI) without clinical
symptoms (90%) or as TB with clinical symptoms (10%) [3,4]. Similarly, it is believed that Mtb
alters its gene expression profile during different stages of infection due to interaction with
various human host defence mechanisms, consequently also causing variation in the antigen
repertoire exposed to the human immune system [5–9].
Understanding human immunity to Mtb infection, including immunity to potential novel
TB vaccine antigens, during different stages of infection and sustainability of immunity over
time, is considered necessary to develop a novel TB vaccine capable of halting progression
from Mtb infection to TB [5]. Currently, only a limited number of Mtb antigens have been
exploited for use in novel TB vaccines [5,6,10,11], with ESAT-6, TB10.4, and Ag85A-B anti-
gens represented in numerous vaccine candidates [12]. Furthermore, little is known about the
change in immune response to Mtb antigens when infection occurs and before TB disease
develops. Hence, there is a continued need for expanding knowledge regarding the clinical rel-
evance of immunity to Mtb antigens for future use in vaccine development.
The Mtb genes known to be expressed during different stages of infection include: early
stage antigens (e.g. Ag85B) found to be highly expressed in the early replicative stage of infec-
tion [5,13]; constitutively expressed antigens (e.g. ESAT-6/TB10.4/CFP10) believed to be
expressed throughout all stages of infection [14]; and LTBI antigens believed to be expressed
predominantly when Mtb is quiescent and in a slow or non-replicative stage [5,15]. To our
knowledge, no previous studies have evaluated immunity to Mtb infection by measuring
immune responses to Mtb antigens from all stages in the Mtb infection cycle and change over
time.
Greenland has a high TB incidence and represents a unique setting for Mtb-antigen evalua-
tion as it is most likely free of cross-reacting antigens derived from non-tuberculous mycobac-
teria (NTM), enabling an unbiased evaluation of host immunity [16].
The study aims to evaluate host immunity to Mtb infection among individuals in a TB-
high-endemic region by measuring immune responses to potential TB vaccine antigens
believed to be expressed by the bacterium during different stages of infection, and to observe
sustainability of host immunity over time.
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Methods
Setting, study design and study population
Greenland is an autonomous part of the Kingdom of Denmark, but governed by the Green-
land Self-government. The majority of the population is Inuit (89%) [17]. The population has
universal and free access to health care, including free TB treatment. The study was performed
in the Eastern part of Greenland in the Tasiilaq region with 3,008 inhabitants (1 January 2013)
[17]. The average TB incidence in the study setting was 440/100,000 inhabitants/year from
1982 to 2012 [18]. All live-born children and new residents in Greenland are assigned a unique
personal identification number through the Civil Registration System (CRS) [19], allowing
individual follow-up through all national registers and providing information on e.g. place
and date of birth, sex, place of residence and TB notification. To be categorised as Inuit in the
present study, both parents should be registered as being born in Greenland. Neonatal Bacillus
Calmette-Gue´rin (BCG) vaccination has been a part of the Greenlandic childhood vaccination
programme since 1955, but was discontinued in 1991 and subsequently re-introduced in 1997
due to nationwide policy changes [18,20]. We assume all individuals born in Greenland from
January 1, 1991, to December 31, 1996, to be unvaccinated. The assumption is evaluated else-
where [18].
This was an explorative cohort study and the study population comprised primarily BCG
unvaccinated Greenlanders aged 17–22 years living in Tasiilaq in the years 2012–2013. A pri-
ori, the size of the study population was set at 65 individuals. Among the eligible population
identified through the CRS (N = 206), adequate information on Mtb infection and treatment
status was obtainable for 181 individuals. QuantiFERON1-TB Gold testing (QFT) defined
Mtb infection status (undetected/detected). The eligible study participants were categorised
into four groups: (1) Mtb infection undetectable by QFT (N = 94), (2) ongoing Mtb infection,
non-treated (N = 25), (3) prior Mtb infection, treated for notified TB (N = 41), and (4) prior
Mtb infection, treated with preventive monotherapy (N = 21). Participants were invited
randomly within each of the groups, however with oversampling of individuals with Mtb infec-
tion, and with particular focus on including individuals with ongoing Mtb infection, anticipat-
ing immune responses to Mtb antigens in this group. One week in advance, the participants
received a personal letter of invitation, study information, and a consent form. Participants
were enrolled in October-November 2012 and April 2013, and followed-up with one or two
subsequent assessments in April and/or September 2013. Study staff assessed the participants
at the local hospital and blood samples were obtained at each assessment. All participants were
simultaneously followed-up for TB through national registers.
Assessment of TB, TB treatment status, QFT and definition of Mtb
infection
Information on TB diagnosis and treatment was obtained from the Greenlandic TB notifica-
tion system where cases, following WHO case definitions, are notified to the National Board of
Health with mandatory notification since 1955. Subsequent TB was defined as TB diagnosed
from study enrolment to end of follow-up. Information on preventive monotherapy and QFT
results prior to enrolment was obtained from medical records and the national laboratory
database; results originating from routine TB diagnostics, contact tracing and population
screening. The Greenlandic treatment regimens, curative treatment (TB) and preventive
monotherapy, follow WHO recommendations.
The Greenlandic healthcare system and the present study used the commercialised QFT
to=assess detectable Mtb infection. QFT is a standardised IGRA measuring T-cell-induced
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immune responses to the Mtb antigens ESAT-6, CFP10, and TB7.7 [14,21,22]. QFTs were ana-
lysed at Statens Serum Institut, Denmark (study QFTs) and at the Central Laboratory, Queen
Ingrid’s Hospital, Nuuk (prior QFTs) following the instructions of the manufacturer [22].
Ongoing Mtb infection was defined as a positive QFT (prior testing or at enrolment) with-
out having received treatment (curative or preventive). Prior Mtb infection was defined as
either having notified TB prior to enrolment or having received preventive monotherapy prior
to enrolment. At enrolment, Mtb infection stages were defined as: (1) Mtb infection undetect-
able by QFT, (2) ongoing Mtb infection, non-treated, and (3) prior Mtb-infection, treated. The
category prior Mtb infection included both participants treated for notified TB and with pre-
ventive monotherapy. We compared groups by Mtb infection status (Mtb infection undetect-
able by QFT vs. Mtb infection) and among Mtb-infected by treatment status (prior Mtb
infection vs. ongoing Mtb infection).
Mtb antigens, laboratory analyses and definition of immune responses
Selected Mtb antigens. We evaluated immune responses to 15 antigens categorised as fol-
lows: early Mtb infection stage antigens (Rv0203, Rv0642, Rv1196), constitutively expressed
antigens (ESAT-6, CFP10, Rv3614, Rv3849, Rv3865, Rv3872), LTBI antigens (Rv1284, Rv2031,
Rv2244, Rv2659, Rv2660c) and Mtb complex antigens (PPD). Currently, only ESAT-6, CFP10
and PPD are available in commercial tests. ESAT-6 and CFP10 were categorised as QFT anti-
gens. Rv0203, Rv0642, Rv1196, Rv3614, Rv3849, Rv3865, Rv3872, Rv1284, Rv2031, Rv2244,
Rv2659, and Rv2660c were categorised as non-QFT antigens. The non-QFT antigens were
selected in June 2012 using the TB database at http://www.tbdb.org/. The expression profiles
of the individual antigens were compared with the expression profile of Ag85B, which is a sig-
nature antigen of early expression [13]. The correlation of the individual antigens with Ag85B
subsequently designated the antigen groups described above. Additional information on the
selected antigens are presented in Table A in S1 File.
Laboratory analyses. Immune responses to Mtb antigens were assessed using a 7-day
interferon gamma release assay (IGRA) with whole blood (WB) antigen stimulation done on
site in Greenland and subsequent quantification of T-cell-induced interferon gamma (IFNy)
by enzyme-linked immunosorbent assay (ELISA) in Denmark. In brief, WB was incubated
with antigens in final peptide or PPD concentration 5 μg/ml in 200 μL volumes for 7 days
at 37˚C in a humidified incubator at 5% CO2. All samples were done in triplicates. WB incu-
bated without antigen (NIL) and WB incubated with phytohaemagglutin (PHA, 5 μg/ml) were
used as negative and positive controls [16]. Antigens were prepared as peptide pools with char-
acteristics presented in Table A in S1 File. Rv0642, Rv1196 and Rv2659 were divided into
pools a, b, and/or c due to antigen size, achieving peptide pools with a maximum of 19 peptides
(median = 13). In Greenland, samples were stored at -20˚C before and during transport to
Denmark; transportation took place within one month. In Denmark, samples were stored at
-80˚C until ELISA analysis. The laboratory analysis is described in detail elsewhere [16].
Definition of immune responses, conversion and reversion. Immune responses were
calculated as medians (IFNy values, pg/ml) for triplicate wells. An immune response to Mtb
antigens was defined as positive if IFNy was >19.5 pg/ml AND fulfilled the following criteria:
a) response (after NIL (background) subtraction) >41.5 pg/ml OR b) the ratio (between
response and NIL) >antigen-specific cut-points estimated by mixture models. Antigen con-
version was defined as converting from a negative to a positive immune response; antigen
reversion was defined as reverting from a positive to a negative immune response. Immune
responses to antigen pools (Rv0642, Rv1196, Rv2659) or groups of antigens (QFT, constitutive,
early, LTBI, Rv2659/Rv1196) were defined as having an immune response to at least one of the
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pools or antigens, and IFNy response magnitude was defined by the maximum response.
Based on our findings we additionally evaluated two combinations of antigens: Rv2659/
Rv1196 (as described above) and CFP10-Rv2659/Rv1196 requiring having an immune
response to both CFP10 and Rv2659/Rv1196.
Antigen specific cut-points. The cohort of the 65 study participants were nested in a
larger cohort study of 911 Greenlanders [16] and the definition of a positive immune response
was derived from the sum of immunological data from this larger study population. In the
cohort of 911 Greenlanders, 19.5 pg/ml was the observed 95% quantile of the NIL IFNy values
and 41.5 pg/ml was the observed 99% quantile of the NIL IFNy values [16]. The antigen
specific cut-points estimated by mixture models were based on the ratios between antigen
stimulated wells and NIL wells for the 65 participants at first assessment, except for Rv1284,
Rv2660c, Rv2659, Rv3849, and PPD. For Rv3849 the antigen specific cut-point was estimated
using information from all three assessments, as estimation convergence could not be achieved
by first assessment information only. For Rv1284, Rv2659, Rv2660c, and PPD the antigen spe-
cific cut-points were estimated using immunological data from the cohort of 911 Greenlanders
described above. The logarithm to the ratios were calculated as log((IFNy in antigen stimulated
wells+0.1)/(IFNy in NIL wells+0.1)), 0.1 was added IFNy responses on both sides of the frac-
tion to allow for IFNy values of zero. The distribution of the logarithm to the ratio was mod-
elled as a mixture of two normal distributions with the same variance but different means
estimated in a mixture model by an EM-algorithm using the R package mixtool [23,24]. The
two normal distributions were interpreted as the positive immune responses and the negative
immune responses, allowing for estimation of sensitivity and specificity for a given cut-point.
The estimation process is illustrated elsewhere [16]. In the analyses, the cut-point ratios were
chosen so that the estimated specificity was 95%. The estimated cut-points used in the defini-
tion of a positive immune response in the analyses are presented in Table A in S1 File. The
method is described in detail elsewhere [16].
Statistical analysis
Homogeneity among participants with Mtb antigen immune responses (prior Mtb infection
vs. ongoing Mtb infection) was evaluated for prevalence by logistic regression and for IFNy
response by Kruskal-Wallis test. The annual risk of conversion was estimated from the conver-
sion rate. The conversion rate was estimated among participants with a negative immune
response at enrolment with at least two subsequent assessments using binomial regression
with a complementary log-log link and with the logarithm of the observation time as offset.
The annual risk of reversion was estimated in a similar way, except it was based on participants
with a positive immune response at enrolment or at second assessment, with at least one subse-
quent assessment. Associations between Mtb infection groups and risk of conversion/reversion
were evaluated using the above binomial regression. The average annual conversion risk for a
group of antigens was estimated using the same model but with data for each antigen included
in the analyses assuming similar conversion rates for all antigens. Associations between posi-
tive antigen immune responses and subsequent TB were evaluated by Hazard Ratios (HRs)
using Cox regression with age as underlying time scale, with adjustment for Mtb infection sta-
tus (undetectable/detectable) and with follow-up until the first of the following events: TB,
death or end of follow-up (31 December 2014). In the analyses of immune responses at enrol-
ment (negative/positive), all participants were included and followed from enrolment. In the
analyses of conversion and reversion during follow-up (no/yes), all participants assessed at
least twice were included; follow-up began at second assessment and exposure was allowed to
be time-dependent. If only first and third assessments were available, follow-up began at the
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midpoint between first and third assessment with the assumption that any observed change
between first and third assessment happened before beginning of follow-up. A substantial
CPF10 and ESAT-6 increase was defined as>75% quantile of changes for all participants
between first and second assessment. All tests and 95% confidence intervals (CIs) were based
on Wald statistics. Analyses were performed using the R software.
Ethical considerations
The study fulfilled the Helsinki Declaration II. Written and informed consent was given by all
participants and by parents or legal guardians of children <age 18. Child acquiescence was
required for children <age 18. All participants with a positive QFT were referred to the local
hospital for further evaluation. In the Tasiilaq region, individuals with a positive QFT but with-
out clinical indication of TB, were followed closely by the TB health personnel with clinical
assessments. The Commission for Scientific Research in Greenland (approval No. 2012–4)
and the Danish Data Protection Agency approved the studies.
Results
Overall, 65 participants were enrolled (60 in October-November 2012 and 5 in April 2013).
Table 1 and Table B in S1 File present characteristics at enrolment and the 65 participants
were categorised as follows into one of three groups: 1) undetectable Mtb infection at enrol-
ment as measured by QFT: 11 (17%), 2) ongoing Mtb infection: 22 (34%) and 3) prior Mtb
infection: 32 (49%). The median age was 19 years and few participants were BCG-vaccinated
N = 6 (9%). More women had received prior treatment as compared with men (61% vs. 34%)
and more men developed TB during follow-up as compared with women (14% vs. 3%). Partic-
ipation was not associated with sex or BCG vaccination (Table C in S1 File).
Immunity at enrolment
Among all 65 participants, 42 (65%) had an immune response to at least one of the 12 non-
QFT antigens and 34% to three or more non-QFT antigens (Fig A in S1 File). Table 2 presents
the prevalence of positive immune responses and the median IFNy response by Mtb infection
stage at enrolment regardless of subsequent TB, reversion of immune responses, or QFT con-
version during follow-up. The prevalence was highest for PPD and QFT antigens (range 45%-
80%) and lowest for constitutively expressed antigens (range 2%-13%). Rv1196 and Rv2659
had the highest prevalence, while immune responses to Rv2660c were not detectable in the
study population. Four participants without detectable Mtb infection at enrolment had
immune responses to Rv2031, Rv2659, and Rv3849. Prevalence and IFNy response levels did
not differ among participants with prior as compared with ongoing Mtb infection, except for
the QFT IFNy response level, which was significantly higher for participants with ongoing Mtb
infection (Table 2). For the distribution of IFNy responses at enrolment, see Fig 1; immune
responses among participants with subsequent TB have been highlighted in red, all occur
among participants with ongoing Mtb infection at enrolment.
Immunity over time and during different stages of infection
Of the 65 participants, 60 (92%) were assessed at least two times and 49 (75%) three times dur-
ing 11 months (Table 1). Tables 3 and 4 present the estimated annual conversion and reversion
risk during follow-up. The risks are cumulative risks, e.g. risk of conversion is the risk of ever
converting, regardless of subsequent reversion, among participants who were without immune
responses to Mtb antigens at enrolment. Overall, there was a high annual conversion and
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reversion risk for all non-QFT antigens; conversion (range 6–69%) and reversion (range 41–
95%). For participants reverting from first to second assessment, the median IFNy level at sec-
ond assessment was 7.4 pg/ml (Fig B in S1 File), thus the high reversion risk could not be
ascribed to IFNy responses decreasing to levels just below the cut-point.
Table 1. Characteristics at enrolment by Mtb infection status among 65 young adults in East Greenland.
Characteristics at
enrolment
All All
Mtb infection undetectable
by QFT
Mtb infection Subsequent
TB
All Ongoing Prior N
Non-
treated
Treated with preventive
monotherapy
Treated for
notified TB
N N N N N N
All 65 11 54 22 12 20 5
Sex
Women 36 5 31 9 8 14 1
Men 29 6 23 13 4 6 4
Age (years)
16–19 43 8 34 11 8 15 4
20–22 22 3 18 11 2 5 1
Ethnicity
Inuit 64 10 54 22 12 20 5
Non-Inuit 1 1 0 0 0 0 0
BCG vaccination
No 58 10 48 19 12 17 4
Yes 6 0 6 3 0 3 1
Unknown 1 1 0 0 0 0 0
Year of:
prior positive QFT or TST/ notified TB
1996–2009 15 - 15 12 0 3 1
2010–2012 37 - 37 10 12 15 2
2012
In TB treatment 3 - - - - 3 -
None 11 11 0 0 0 0 2
Clinical information
Pulmonary TB 16 4
Extra-pulmonary TB 4 1
Assessed in
September 2012 60 11 49 18 12 19 5
April 2013 57 9 48 20 10 18 4
September 2013 57 10 47 20 9 18 5
Number of times assessed
Two 60 10 50 20 11 19 5
Three 49 9 40 16 8 16 4
Subsequent TB: TB notified to the National TB register at any point from study enrolment to end of follow-up.
Mtb infection was defined a positive QFT (prior or at enrolment) and categorised as ongoing (non-treated) or prior (treated for notified TB or having received
preventive monotherapy).
QFT: QuantiFERON®-TB Gold test. TST: Tuberculin skin test. BCG: Bacillus Calmette-Gue´rin vaccination status estimated from birth cohort.
For further categorisation of year of QFT or notified TB/preventive monotherapy among participants at enrolment, please see Table B in S1 File.
https://doi.org/10.1371/journal.pone.0177906.t001
The dynamics of immune responses to Mycobacterium tuberculosis during different stages of infection
PLOS ONE | https://doi.org/10.1371/journal.pone.0177906 June 1, 2017 7 / 22
Table 2. Prevalence of immune responses and median IFNy response among participants at enrolment by Mtb infection status, among 65 young
adults in East Greenland.
All Mtb infection
undetectable by
QFT
Mtb infection Prevalence:
prior vs.
ongoing
P valuea
IFNy
response:
prior vs.
ongoing
P valueb
All Ongoing, non-
treated
Prior, treatedh
% (N) IFNy
response
median
(range)
pg/ml
% (N) IFNy
response
median
(range)
pg/ml
% (N) IFNy
response
median
(range)
pg/ml
% (N) IFNy
response
median
(range)
pg/ml
% (N) IFNy
response
median
(range)
pg/ml
All (65) (11) (54) (22) (32)
QFT 80 (52) 209 (16–
400)
0 (0) - 96 (52) 210 (16–
400)
95 (21) 400 (16–
400)
97 (31) 157 (16–
400)
0.79 0.01
7-day IGRAs
PPDc 80 (51) 2361
(178–
4366)
0 (0) - 94 (51) 2361
(178–
4366)
95 (21) 2457
(310–
4366)
94 (30) 2177
(178–
3741)
0.71 0.31
QFT Agsd
(anye/
maxf)
80 (52) 850 (47–
4156)
0 0 - 96 (52) 850 (47–
4156)
95 (21) 1099 (47–
4156)
97 (31) 764 (80–
3647)
0.79 0.24
ESAT-6
78 (51) 764 (47–
3647)
0 (0) - 94 (51) 764 (47–
3647)
95 (21) 1099 (47–
3061
94 (30) 756 (80–
3647)
0.79 0.41
CFP10
45 (29) 429 (46–
4156)
0 (0) - 54 (29) 429 (46–
4156)
55 (12) 633 (46–
4156)
53 (17) 318 (50–
784)
0.92 0.11
Constitutiveg
(any/
max)
17 (11) 109 (48–
234)
18 (2) 51 (49–
53)
17 (9) 121 (48–
234)
14 (3) 109 (82–
121)
17 (6) 171 (48–
234)
0.62 0.30
Rv3614
11 (7) 89 (42–
215)
0 (0) - 13 (7) 89 (42–
215)
9 (2) 102 (82–
121)
16 (5) 89 (42–
215)
- -
Rv3849c
13 (8) 73 (43–
137)
18 (2) 51 (49–
53)
11 (6) 100 (43–
137)
5 (1) 109 (-) 16 (5) 92 (43–
137)
- -
Rv3865
3 (2) 90 (48–
133)
0 (0) - 4 (2) 90 (48–
133)
0 (0) - 6 (2) 90 (48–
133)
- -
Rv3872
2 (1) 234 (-) 0 (0) - 2 (1) 234 (-) 0 (0) - 3 (1) 234 (-) - -
Early Ags
(any/
max)
40 (26) 95 (44–
617)
0 (0) - 48 (26) 95 (44–
617)
54 (12) 83 (44–
617)
44 (14) 106 (46–
329)
0.44 0.72
Rv0203c
22 (14) 74 (43–
329)
0 (0) - 26 (14) 74 (43–
329)
36 (8) 63 (44–
232)
19 (6) 85 (43–
329)
- -
Rv0642
5 (3) 87 (69–
130)
0 (0) - 6 (3) 87 (69–
130)
9 (2) 78 (69–
87)
3 (1) 130 (-) - -
Rv1196
35 (23) 81 (45–
617)
0 (0) - 43 (23) 81 (45–
618)
41 (9) 81 (48–
618)
44 (14) 87 (45–
329)
0.84 0.38
LTBI Ags
(any/
max)
55 (36) 105 (44–
918)
36 (4) 61 (50–
88)
60 (32) 128 (44–
918)
60 (13) 106 (47–
304)
60 (19) 177 (44–
918)
0.98 0.60
Rv2031c
20 (13) 79 (47–
624)
9 (1) 50 (-) 22 (12) 129 (47–
624)
23 (5) 61 (47–
207)
22 (7) 184 (66–
624)
- -
Rv2244
6 (4) 80 (46–
120)
0 (0) - 7 (4) 80 (46–
120)
5 (1) 104 (-) 9 (3) 57 (46–
120)
- -
Rv1284
15 (10) 67 (47–
918)
0 (0) - 19 (10) 67 (47–
918)
14 (3) 47 (47–
72)
22 (7) 71 (50–
918)
- -
(Continued )
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The high annual conversion and reversion risks illustrate that immune responses to Mtb
antigens increase and decrease to a considerable extent during infection, thus these immune
responses are not necessarily sustained in host immunity as an individual with Mtb infection
can have high levels of immune responses to specific Mtb antigens at one point in time and
low levels of immune responses below a defined test cut-point at another point in time regard-
less of treatment. The annual conversion and reversion risks did not differ by Mtb infection
status (Table 3 and Table E in S1 File), but among participants with ongoing Mtb infection, the
annual conversion risk was significantly higher for constitutive antigens (p = 0.048), the early
stage antigen Rv0203 (p = 0.02) the LTBI antigen Rv2031 (p = 0.02) as compared with partici-
pants with prior Mtb infection. In addition, the annual reversion risk was significantly higher
for Rv2031 among participants with ongoing Mtb infection.
To summarise the general level of non-QFT antigen conversion presented in Table 3, we
calculated an estimate including all conversions for all antigens or a group of antigens as a
weighted average for groups of antigens. In comparison, the annual conversion risks from
Table 3 are cumulative risks for antigen conversion within each antigen group. For all partici-
pants, the weighted average conversion risk for non-QFT antigens was 22% based on annual
conversion risks of 6–69% for the single antigens (Table 3), the weighted average conversion
risk for the antigens in each group was 29% for early stage antigens, 13% for constitutive anti-
gens and 24% for LTBI antigens. As different Mtb antigens are expressed during different
stages of infection, we anticipated more conversion (change in immune response over time)
Table 2. (Continued)
All Mtb infection
undetectable by
QFT
Mtb infection Prevalence:
prior vs.
ongoing
P valuea
IFNy
response:
prior vs.
ongoing
P valueb
All Ongoing, non-
treated
Prior, treatedh
% (N) IFNy
response
median
(range)
pg/ml
% (N) IFNy
response
median
(range)
pg/ml
% (N) IFNy
response
median
(range)
pg/ml
% (N) IFNy
response
median
(range)
pg/ml
% (N) IFNy
response
median
(range)
pg/ml
Rv2659
43 (28) 74 (43–
491)
36 (4) 61 (43–
88)
44 (24) 92 (44–
491)
41 (9) 111 (52–
304)
47 (15) 62 (44–
491)
0.66 0.42
Rv2660c
0 (0) - 0 (0) - 0 (0) - 0 (0) - 0 (0) -
Combination of antigens
Rv2659/
Rv1196
55 (36) 97 (43–
617)
36 (4) 61 (43–
88)
30 (32) 110 (44–
617)
54 (12) 130 (48–
617)
63 (20) 90(44–
491)
0.56 0.24
a P values relate to homogeneity test for odds of having an immune response to the selected Mtb antigen among participants with Mtb infection; prior vs.
ongoing.
b P values relate to homogeneity for IFNy medians evaluated by the Kruskal-Wallis test among participants with Mtb infection; prior vs. ongoing.
c One donor missing one stimulation.
d Ags: antigens.
e Immune responses for groups of antigens (QFT, constitutive, early, LTBI, Rv2659/Rv1196) were defined as having an immune response to at least one of
the antigens and
fthe IFNy response magnitude was defined by the maximum response.
g Constitutive antigens.
h For numbers on participants treated with preventive monotherapy and participants treated for notified TB, please see Table D in S1 File.
https://doi.org/10.1371/journal.pone.0177906.t002
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among participants with early stage antigen conversion. However, participants with and with-
out early stage antigen immune responses at enrolment had similar levels of subsequent aver-
age conversion risk for constitutive (23% vs. 25%) and LTBI antigens (19% vs. 10%). When
including only participants with QFT conversion during follow-up (N = 3) in the analysis, the
weighted average conversion risk for non-QFT antigens was 40% as compared to 22% for all
participants, however numbers are small.
Immunity and risk of subsequent TB
During a total of 132 person-years, 5 (8%) participants were notified with TB, corresponding
to an average TB incidence of 3,788/100,000 participants/year. Fig 2A–2E present changes in
the immune response to Mtb antigens as infection occurs and just before disease develops in
five participants with subsequent TB and one participant with QFT conversion during follow-
up. The five participants were either QFT-positive at enrolment or became QFT-positive dur-
ing the study period. All five had an immune response to the early stage antigen Rv1196 or
LTBI antigen Rv2659. Four out of five experienced an increase in CFP10 response prior to TB
development. Overall, the average conversion risk for non-QFT antigens among participants
with subsequent TB was 27% vs. 21% for participants without subsequent TB, reflecting no dif-
ference in non-QFT antigen conversion by subsequent TB.
For non-QFT antigens, neither having an immune response to Mtb antigens upon enrol-
ment nor a history of conversion or reversion during follow-up was found to be associated
with risk of subsequent TB (Table 5). A history of QFT or ESAT-6 conversion was associated
with an increased risk of TB, while a history of CFP10 conversion was not. However, a history
Fig 1. IFNy responses among participants with Mtb antigen immune responses at enrolment among participants with Mtb infection. Three
participants (red) categorised at Mtb infected non-treated develop TB. *The two most prevalent non-QFT antigens in each group. All values are antigen
responses after background subtraction in pg/ml with medians.
https://doi.org/10.1371/journal.pone.0177906.g001
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of a substantial CFP10 response increase of103.4 pg/ml was associated with a 10-fold
increased risk of TB (Table 5, Fig 2A–2E). In comparison, this association was not found for
the non-QFT antigens Rv1196 or Rv2659. We further investigated the timing of QFT conver-
sion relative to the timing of subsequent TB. Three participants had QFT conversion during
follow-up (Fig 2D–2F), and using this to determine the approximate time of Mtb infection
[25], the time from infection to TB was 7 and 10 months for two participants, while no TB was
observed in one participant during 21 months of follow-up (Fig C in S1 File). Similarly, among
Table 4. Estimated annual reversion risk during follow-up, among participants with Mtb antigen
immune response at least once and with subsequent assessment, regardless of Mtb infection status.
Estimated annual reversion risk Participants with Mtb antigen
immune response at least once
and with subsequent
assessment
Revert during follow-up Total
% N N
QFT 0 0 49
7-day IGRAs
PPD 5 2 52
QFT antigens
Anya 5 2 53
ESAT-6 5 2 52
CFP10 34 10 35
Constitutive antigens
Anya 60 8 16
Rv3614 65 5 9
Rv3849 91 11 14
Rv3865 46 1 3
Rv3872 76 3 5
Early antigens
Anya 44 13 39
Rv0203 52 8 19
Rv0642 45 2 6
Rv1196 48 13 36
LTBI antigens
Anya 41 16 50
Rv2031 78 13 19
Rv2244 95 9 9
Rv1284 93 12 14
Rv2659 49 17 47
Rv2660c - 0 0
Combinations of antigens
Rv2659/1196 28 11 54
CFP10 and Rv2659/Rv1196 55 14 32
The annual reversion risk was significantly higher for Rv2031 (p<0.05) among participants with ongoing
(non-treated) Mtb infection as compared with participants with prior (treated) Mtb infection, see Table E in S1
File.
a A positive immune response to groups of antigens (QFT, constitutive, early, LTBI, Rv2659/Rv1196)
required all of the antigen immune responses within the group to be above the cut-point.
https://doi.org/10.1371/journal.pone.0177906.t004
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participants with a substantial CFP10 increase during follow-up (N = 21), we observed TB in
four participants 7, 10, 10 and 10 months following CFP10 increase, while no TB was observed
in 17 participants until end of follow-up (Fig D in S1 File).
Discussion
In this study, we found that immunity to Mtb infection, measured by immune responses to
Mtb antigens representing different stages of Mtb infection, revealed considerable fluctuation
in host immunity with high conversion and reversion. Participants with ongoing Mtb infection
at enrolment experienced significantly higher conversion as compared with participants with
prior infection. High non-QFT antigen conversion was also observed at the time of infection
defined by QFT conversion. Fluctuations in immune responses to the studied non-QFT anti-
gens were not associated with subsequent TB.
The studied non-QFT antigens were a priori considered to be promising novel TB antigen
candidates and were believed to be expressed during different stages of Mtb infection [26–38].
Fig 2. A-F. Changes in immune response to Mtb antigens as infection occurs and just before disease develops. Immune responses to Mtb
antigens are shown in pg/ml after background subtraction by month of follow-up before and after TB notification or QFT conversion. Information on five
participants with subsequent TB during follow-up and one participant with QFT conversion during follow-up are presented. A-C) Participants with
ongoing Mtb infection at enrolment and subsequent TB during follow-up. D-E) Participants with Mtb infection undetectable by QFT at enrolment and
subsequent TB during follow-up. F) One participant with Mtb infection undetectable by QFT at enrolment and with QFT conversion during follow-up.
Information on symptom onset, clinical assessment at TB diagnosis and timing of TB diagnosis is provided.
https://doi.org/10.1371/journal.pone.0177906.g002
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Table 5. Crude Hazard ratios (HRs) for subsequent TB (N = 5) by Mtb antigen immune responses at
enrolment, history of conversion and history of reversion during follow-up among 60 participants
assessed more than once.
Participants with Mtb
antigen immune
response at enrolment
History of conversion
during follow-up
History of reversion
during follow-up
All TB All TB All TB
% %
(N)
HR (95%
CI)
P %a %
(N)
HR (95%CI) P %a %
(N)
HR (95%
CI)
P
QFT 80 60
(3f)
0.35
(0.05–
2.53)
0.30 3 40
(2)
16.14
(1.42–
183.00)
0.03 0 0
(0)
- -
7-day IGRAs
PPD 80 60
(3)
0.38
(0.05–
2.85)
0.35 11 40
(2)
5.12(0.64–
41.20)
0.13 3 0
(0)
- -
QFT antigens
Any 80 60
(3)
0.35
(0.05–
2.53)
0.30 10 40
(2)
9.59 (1.29–
71.33)
0.03 3 0
(0)
- -
Esat-6 78 60
(3)
0.37
(0.05–
2.68)
0.33 12 40
(2)
9.59 (1.29–
71.33)
0.03 3 0
(0)
- -
Increaseb - - - - - 40
(2)
1.60 (0.24–
10.74)
0.63 - - - -
CFP10 45 20
(1)
0.29
(0.03–
2.87)
0.29 18 60
(3)
4.17 (0.64–
27.02)
0.13 14 20
(1)
2.35
(0.24–
23.33)
0.47
Increasec - - - - - 80
(4)
10.06
(1.05–
96.25)
<0.05 - - - -
Constitutive Ags
Any 17 20
(1)
1.19
(0.13–
11.1)
0.88 17 40
(2)
2.64 (0.41–
17.07)
0.31 11 20
(1)
2.22
(0.21–
23.89)
0.51
Rv3614 11 0
(0)
- - 14 40
(2)
2.63 (0.42–
16.27)
0.30 8 0
(0)
- -
Rv3849 13 20
(1)
1.53
(0.17–
13.99)
0.71 13 0
(0)
- - 17 0
(0)
- -
Rv3865 3 0
(0)
- - 4 0
(0)
- - 2 0
(0)
- -
Rv3872 2 0
(0)
- - 8 20
(1)
4.64 (0.40–
54.21)
0.22 3 20
(1)
- -
Early Ags
Any 40 20
(1)
0.49
(0.05–
4.63)
0.53 30 60
(3)
6.56 (0.71–
60.13)
0.10 19 20
(1)
1.52
(0.16–
14.66)
0.72
Rv0203 22 20
(1)
1.34
(0.13–
13.5)
0.80 17 40
(2)
4.15 (0.55–
30.98)
0.17 12 0
(0)
- -
Rv0642 5 0
(0)
- - 11 20
(1)
3.55 (0.32–
29.44)
0.30 3 20
(1)
- -
Rv1196 35 20
(1)
0.58
(0.06–
5.43)
0.64 33 60
(3)
2.37 (0.39–
14.27)
0.34 19 20
(1)
1.52
(0.16–
14.66)
0.72
(Continued )
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In this study, we provided the first comprehensive longitudinal data in a real-life setting for
these antigens and the first human data for Rv0642, Rv2244, Rv3614, and Rv3649. Currently,
only Rv2031 and Rv2659 have been evaluated longitudinally in humans [39,40], while Rv2660
and Rv1196 are present in two novel TB vaccines in clinical trial [7,41]. Our study documented
Table 5. (Continued)
Participants with Mtb
antigen immune
response at enrolment
History of conversion
during follow-up
History of reversion
during follow-up
All TB All TB All TB
% %
(N)
HR (95%
CI)
P %a %
(N)
HR (95%CI) P %a %
(N)
HR (95%
CI)
P
Increased - - - - - 40
(2)
1.56 (0.25–
9.87)
0.64 - - - -
LTBI Ags
Any 55 60
(3)
1.22
(0.20–
7.35)
0.83 41 40
(2)
0.88 (0.14–
5.45)
0.89 23 40
(2)
2.81
(0.42–
18.83)
0.29
Rv2031 20 20
(1)
0.88
(0.10–
8.04)
0.91 25 40
(2)
2.11 (0.32–
13.77)
0.44 18 40
(2)
3.15
(0.49–
20.38)
0.23
Rv2244 6 0
(0)
- - 12 0
(0)
- - 13 0
(0)
- -
Rv1284 15 20
(1)
1.76
(0.19–
16.43)
0.62 12 20
(1)
1.62 (0.17–
15.75)
0.68 17 20
(1)
1.09
(0.12–
11.03)
0.94
Rv2659 43 60
(3)
2.67
(0.39–
14.28)
0.35 50 40
(2)
0.45 (0.06–
3.10)
0.42 24 40
(2)
2.34
(0.32–
16.82)
0.40
Increasee - - - - - 20
(1)
0.77 (0.08–
7.16)
0.82 - - - -
Combinations of antigens
Rv2659/
Rv1196
55 60
(3)
1.47
(0.24–
9.19)
0.68 44 40
(2)
0.64 (0.10–
4.01)
0.63 16 20
(1)
1.61
(0.16–
16.32)
0.69
CFP10 and
Rv2659/Rv1196
31 20
(1)
0.64
(0.06–
6.84)
0.71 30 60
(3)
2.51 (0.39–
16.31)
0.34 19 40
(2)
5.53
(0.67–
46.46)
0.11
HRs relate to the risk of TB during follow-up with participants without detectable Mtb antigen immune
responses as reference.
Adjustment for Mtb infection status did not alter the results except for the ESAT-6 conversion association.
After adjustment ESAT-6 conversion was not significantly associated with risk of subsequent TB although
the HR only decreased marginally HR: 9.09 (0.64–129.28), p = 0.10, see Table F in S1 File.
CI: Confidence interval. Ags: Antigens
a % person years: Proportion of exposure time in person-years during a total of 96.16 person years of follow-
up
b ESAT-6 increase > 587 pg/ml.
c CFP10 increase > 103 pg/ml.
d Rv1196 increase > 97 pg/ml.
e Rv2659 increase > 126 pg/ml
f In Fig 2A–2F we present immune responses and clinical information (including information on treatment) for
each of the participants who develop TB during follow-up and the three participants who have QFT
conversion during follow-up.
https://doi.org/10.1371/journal.pone.0177906.t005
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that levels of conversion for non-QFT antigens are high during all stages of Mtb infection. The
same was found for reversion, indicating that reversion may be a part of the natural fluctua-
tions within the host immune response during Mtb infection. This is supported by the finding
that reversion was not associated with decreased risk of subsequent TB and therefore not as
proposed an indicator of an ability to contain infection [25,42].
Our findings suggest that the Mtb antigen repertoire exposed to the immune system during
natural infection is very versatile and dynamic, and that the studied Mtb antigens are expressed
during all infection stages. None of the non-QFT Mtb antigens were associated with infection
stage or disease. For Rv0203, Rv2031, and any early stage antigen, conversion of immune
responses were associated with ongoing Mtb infection, however the risk of reversion of
immune responses was high for the same antigens. This implies that longitudinal and stage-
specific evaluation of new vaccine and diagnostic Mtb antigens is necessary and supports the
use of multiple antigens in novel TB vaccines.
Longitudinal studies on changes in immune responses to Mtb antigens are few and not con-
clusive. Only immune responses towards the non-QFT antigens Rv2659 and Rv2031 have
been evaluated longitudinally among humans [39,40]. IFNy responses to Rv2659 and Rv2031
have been reported to increase after one and/or 40 weeks of isoniazid treatment (N = 60), and
increase in Rv2031 IFNy levels among TB contacts (non-treated) as well as TB patients (during
treatment) was reported during 12 months in a study from Ethiopia, however after 12 months
the IFNy levels were comparable to initial IFNy levels among healthy controls from a TB-
endemic region (N = 363) [39,40]. These studies only evaluated median values of IFNy
responses and neither prevalence nor conversion/reversion. In the present study, we find a
very high level of reversion for Rv2031 of 78%, which might make cross-sectional assessment
of immune responses to Rv2031 and median IFNy levels difficult to interpret.
The finding that a substantial CFP10 response increase was associated with a 10-fold risk of
subsequent TB has, to our knowledge, not previously been described in humans. However, the
hypothesis emerged after data analysis and is based on small numbers which should be taken
into account. Lin et al observed a significantly higher production of IFNy in response to
CFP10 in peripheral blood mononuclear cells six weeks after Mtb infection in non-human pri-
mates (NHP) who developed TB compared with those who did not [43]. Thus, the role of
CFP10 increase may be a target for examination in other independent studies, and if the above
findings are confirmed, CFP10 response increase might be a potential marker for when and
among whom preventive TB treatment should be initiated.
Based on the above evaluation of antigen dynamics, we cautiously suggest four characteris-
tics of host immunity to Mtb infection. Mtb antigens exposed to the host during natural infec-
tion may be most potent at the time of infection defined by QFT conversion, reflecting an
abrupt primary activation of the immune system at establishment of infection with bacterial
replication affecting the host response. Participants with ongoing Mtb infection have a signifi-
cantly higher level of antigen conversion, which might reflect a higher degree of bacterial repli-
cation during natural Mtb infection when left untreated, leading to the presumption that these
individuals might be more susceptible to TB risk factors with suppression of cellular immu-
nity. The substantial fluctuations observed in immune responses to non-QFT antigens suggest
that host immunity among individuals with prior and ongoing Mtb infection is of a less dor-
mant character than anticipated, a finding also described in NHP [44]. Finally, preceding pro-
gression from Mtb infection to TB, there is an alteration in immune activity, which in this
study is made evident by an increase in CFP10 response. These findings contribute with
important insight into the dynamics of the natural human immunity during Mtb infection in
the absence of an animal model with the ability to capture the full spectrum of human immune
characteristics of infection and disease [4].
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This study has several strengths; it is unique by being a follow-up study in a setting with
high TB transmission, among largely BCG-unvaccinated and NTM-unexposed individuals
selected by Mtb infection stage. Stratified random sampling optimised the comparison of Mtb
infection stages; however, small numbers limited the statistical power. Several features of the
design minimised information bias. Information was obtained from registers, medical records
and assessment at enrolment. Assessment of QFT, QFT antigens (ESAT-6, CFP10) and PPD
alongside with novel non-QFT antigens contributed as additional assay controls, which
allowed for an evaluation of the internal validity in the absence of a commercial assay. The def-
inition of a positive immune response used in this study was conservative [16]. Furthermore,
the observed reversions were substantial and found not to be caused by responses decreasing
to levels just below the cut-point. Although the estimated levels of immune responses, conver-
sion and reversion are naturally sensitive to the level of the cut-point, their estimated associa-
tions with Mtb infection stages and subsequent TB most likely are not. IFNy as single cytokine
readout used to define immune responses to Mtb antigens is widely discussed [3]. IFNy is a
robust cytokine essential in the adaptive immune response towards TB [45,46]. Furthermore,
IFNy is used as a readout in standardised interferon gamma release assays (IGRAs) [14,21]
and in most of the existing Mtb antigen research. As a supplement, an explorative multiplex
assay including numerous cytokines could have expanded the evaluation [46]. However, to
date, no single cytokine or pattern of cytokines have been shown to be superior, hence we
found IFNy to be a suitable readout in a real-life setting with few laboratory resources
[6,12,25,47–52]. Based on the above, we find it unlikely that the observed findings can be
ascribed to bias.
Conclusion
In conclusion, we found that human immunity to natural Mtb infection evaluated by mea-
sured immune responses to Mtb antigens is very versatile and shows high levels of conversion
and reversion. Our findings suggest that substantial conversion and reversion of immune
responses are part of the dynamics of natural Mtb infection, but not associated with subse-
quent TB development. The fluctuations in human immunity to Mtb antigens during infection
may necessitate longitudinal assessment in the search of TB vaccine candidate antigens to
account for temporary conversions and reversions.
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Table E. Estimated annual reversion risk during follow-up, among participants with Mtb
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Table F. Adjusted Hazard ratios (HRs) for subsequent TB (N = 5) by Mtb antigen immune
response at enrolment, history of conversion and history of reversion during follow-up.
Adjusted for Mtb infection status.
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